Perjeta, formally called pertuzumab, represents a important advancement in treating HER2-positive mammary cancer. It works by blocking a specific pathway on helps cancer cells grow . In contrast to some other HER2-targeted therapies, pertuzumab doesn't directly block the HER2 receptor itself, but